Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL.

Autor: Aldoss I; City of Hope National Medical Center, Duarte, California, United States., Roloff GW; The University of Chicago, Chicago, Illinois, United States., Faramand RG; Moffitt Cancer Center, Tampa, Florida, United States., Kopmar NE; University of Washington, Seattle, Washington, United States., Lin C; Duke University School of Medicine, Durham, North Carolina, United States., Advani AS; Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States., Dekker SE; Fred Hutchinson Cancer Center / University of Washington, Seattle, Washington, United States., Gupta VK; UCLA, Los Angeles, California, United States., O'Connor TE; Loyola University Medical Center, Maywood, Illinois, United States., Jeyakumar N; Stanford University, Stanford, California, United States., Muhsen IN; Baylor College of Medicine, Houston, Texas, United States., Valtis YK; Memorial Sloan Kettering Cancer Institute, New York city, New York, United States., Zhang A; Stanford University School of Medicine, Palo Alto, California, United States., Miller K; Stanford University School of Medicine, Stanford, California, United States., Sutherland KC; Stanford University School of Medicine, Stanford, California, United States., Dykes KC; University of California, San Diego, La Jolla, California, United States., Ahmed M; Cedars Sinai Medical Center, Houston, Texas, United States., Chen EC; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Zambrano H; Sarah Cannon Cancer Institute, Nashville, Tennessee, United States., Bradshaw D; Georgia Cancer Center at Augusta University, Augusta, Georgia, United States., Mercadal S; University of Utah/ Huntsman Cancer Hospital, Salt Lake City, Utah, United States., Schwartz MS; University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States., Tracy SI; University of Minnesota, Minneapolis, Minnesota, United States., Dholaria B; Vanderbilt University Medical Center, Nashville, Tennessee, United States., Kubiak MJ; Georgia Cancer Center of Augusta University, Augusta, Georgia, United States., Mukherjee A; Oncology Hematology Care, Cincinnati, Ohio, United States., Majhail NS; Sarah Cannon Cancer Institute, Nashville, Tennessee, United States., Battiwalla M; Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, Tennessee, United States., Mountjoy L; Colorado Blood Cancer Institute, Denver, Colorado, United States., Malik SA; Texas Transplant Institute, Austin, Texas, United States., Mathews J; Sarah Cannon Transplant and Cellular Therapy Program, Dallas, Texas, United States., Shaughnessy PJ; Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital San Antonio, TX, San Antonio, Texas, United States., Logan A; University of California San Francisco, San Francisco, California, United States., Ladha A; University of Southern California, Los Angeles, California, United States., Stefan M; Cleveland Clinic, Cleveland, Ohio, United States., Guzowski C; Northside Hospital, Atlanta, Georgia, United States., Hoeg RT; UC Davis, Sacramento, California, United States., Hilal T; Mayo Clinic, Phoenix, Arizona, United States., Moore J; University of Rochester Medical Center, Rochester, New York, United States., Connor M; University of Pennsylvania, Philadelphia, Pennsylvania, United States., O'Dwyer KM; University of Rochester Medical Center, Rochester, New York, United States., Hill LC; Baylor College of Medicine, Houston, Texas, United States., Tsai SB; Loyola University Medical Center, Maywood, Illinois, United States., Sasine JP; Cedars-Sinai Medical Center, Los Angeles, California, United States., Solh MM; The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, United States., Lee CJ; University of Utah; Huntsman Cancer Institute, United States., Kota V; Georgia Cancer Center at Augusta University, Augusta, Georgia, United States., Koura D; University of California, San Diego, La Jolla, California, United States., Veeraputhiran M; University of Arkansas Medical Center, Little Rock, Arkansas, United States., Blunk B; Sarah Cannon Cancer Institute, Nashville, Tennessee, United States., Oliai C; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States., Leonard JT; Oregon Health Sciences, Portland, Oregon, United States., Frey NV; Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States., Park JH; Memorial Sloan-Kettering Cancer Center, New York, New York, United States., Luskin MR; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Bachanova V; University of Minnesota, Minneapolis, Minnesota, United States., Galal A; Atlantic Health Network, Morristown, New Jersey, United States., Bishop MR; University of Chicago, Chicago, Illinois, United States., Stock W; University of Chicago, Chicago, Illinois, United States., Cassaday RD; Fred Hutchinson Cancer Center, Seattle, Washington, United States., Pullarkat VA; City of Hope Medical Center, Duarte, California, United States., Shah BD; Moffitt Cancer Center, Tampa, Florida, United States., Muffly L; Stanford University, Stanford, California, United States.

Publikováno v: Blood advances [Blood Adv] 2024 Aug 02. Date of Electronic Publication: 2024 Aug 02.